US Case Reports
Journal of Generic Medicines (2008) 5, 219–228. doi:10.1057/jgm.2008.2; published online 12 February 2008
Aventis v Lupin: Obviousness of purified stereoisomers in view of mixtures thereof
Compiled and written by Goodwin Procter LLP
The Life Sciences Practice at Goodwin Procter LLP provides dedicated, industry-focused representation of life sciences companies at all stages, from start-up through to mature public company, with the full range of representation, including:
Legal advice on corporate and intellectual property matters
Patent portfolio development
Intellectual property litigation
In-licensing and out-licensing of intellectual property
Corporate fi nance transactions
Research and development (R & D) collaborations
Negotiating merger and acquisition (M & A) transactions
Defending against product liability claims
The views expressed in this paper are solely the authors', based on publicly available information.
This paper does not present the views of any former or present client of Goodwin Procter LLP.
This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If any issue in this section is to be relied upon, specifi c advice should be sought. Please contact the Editor:
Strategic IP portfolio and advice and management
Frederick H. Rein
Partner
Goodwin Procter LLP
599 Lexington Avenue
New York, NY 10022
USA
Tel: + 1 212 813 8864
Fax: + 1 212 355 3333
Email: frein@goodwinprocter.com
Goodwin Procter LLP is based in the USA with offices in Boston, Los Angeles, New York, San Diego, Palo Alto, San Francisco and Washington DC.
Frederick H Rein1 and Joseph B Crystal2
1is a partner at Goodwin Procter LLP.
2is an associate at Goodwin Procter LLP.
